Surrozen, Inc. announced that the first subject has been dosed in its two-part Phase I clinical trial for SZN-043 which is in development for the potential treatment of severe alcoholic hepatitis.
[Surrozen, Inc.]
Home Newsletters Hepatic Cell News Surrozen Initiates Dosing in Phase I Clinical Trial of SZN-043 for Severe...
